Nov 16,2020

Real-World Evidence in Oncology – Confirming the Treatment Landscape or Changing it?

In honor of Lung Cancer Awareness Month this November, OncoHealth invites to a webinar dedicated to the evaluation of selected lung cancer clinical trials, using real-world patient data to illustrate why trial outcomes may not be representative.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 23,2020

Pfizer Selects Carevive as First Patient-Reported Outcomes Challenge Winner

Carevive Systems, a leading oncology-focused technology company, has been selected as Pfizer’s (NYSE:PFE) first Patient-Reported Outcomes (PRO) Challenge winner. The Pfizer PRO Challenge is designed to identify innovative PRO-centric platforms and technologies that can provide novel patient-centric support & insight mechanisms for cancer patients. Initially, the collaboration with Pfizer will focus on developing PRO-based longitudinal datasets to uncover insights along the cancer patient journey to support value-based agreements. To generate these data and insights, Carevive will work within its growing network of 26 health system customers, including sites that are participating in the Carevive Oncology Pragmatic Trial Investigator Network (Carevive OPT-IN®).

COLLABORATION PARTNERSHIP

#r&d

#platform

View Analyst & Ambassador Comments
Go to original news
Nov 24,2020

Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials

Patients, who discontinue early, do not benefit from phase I/II clinical trials (early-phase clinical trials (EPCT)). In this study, associations between objective smartphone measurements of physical activity and fitness and early trial discontinuation in patients with cancer participating in EPCT were investigated.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 10,2020

Leeds Deploys Imaging Tech for Advanced NHS Regional Digital Pathology Network

A multi-million pound initiative that is digitising, connecting and applying artificial intelligence to NHS pathology services in the North of England has taken an important step, after Leeds Teaching Hospitals NHS Trust became the first of an initial six trusts in the Northern Pathology Imaging Co-operative (NPIC) to deploy a technology that will underpin the regional programme. Leeds Teaching Hospitals went live with the Sectra picture archiving and communication system (PACS) in October - allowing pathology images to be interrogated by professionals electronically from a range of devices.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Nov 25,2020

Philips Debuts AI-Enabled, Automated Radiology Workflow Suite at RSNA 2020

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced its participation in the RSNA 2020 virtual event, featuring its Radiology Workflow Suite of end-to-end solutions to drive operational and clinical efficiency through the digitalization, integration, and virtualization of radiology. At RSNA 2020, Philips will showcase a coordinated suite of offerings for the first time, introducing key solutions that come together to enhance the entire radiology workflow to address the most pressing operational challenges across diagnostic and interventional radiology.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 18,2020

Leading Pathology Laboratories Deploy Tele-Diagnostics with Philips During the COVID-19 Pandemic

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology samples based on the Philips Digital Pathology scanner and imaging-informatics solutions. Digital images are required to unlock the potential of digital pathology. Remote reviewing of pathological cases is essential to prevent delay in critical patient diagnosis and care, particularly during COVID-19.

PRODUCT

#telehealth

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 23,2020

Bayer Initiates New G4A Digital Health Partnerships Program

Bayer will support five new startup companies as part of the company's G4A Digital Health Partnerships Program. Focus will be on fostering the development of a digital health ecosystem, while driving forward integrated healthcare solutions in the fields of cardiometabolic and renal diseases, oncology, and women's health. The participating digital healthcare companies were selected by Bayer from over 400 applications from over 65 countries based upon current and future strategic fit, development stage and assessment.

View Analyst & Ambassador Comments
Go to original news
Nov 23,2020

Agendia picks Paige for AI cancer pathology platform partnership

Breast cancer diagnostic developer Agendia announced plans to integrate its genomic tests with Paige’s artificial-intelligence-powered pathology services with the goal of building a new digital precision oncology platform. The partnership will aim to develop cloud-based treatment planning tools using data gathered from Agendia’s MammaPrint and BluePrint molecular tests for patients with breast cancer.

COLLABORATION PARTNERSHIP

#r&d

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 04,2020

More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting

Incyte (Nasdaq: INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at the upcoming 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020), held virtually December 5–8, 2020.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 04,2020

Oncohost platform improves immunotherapy response predictions

By analyzing patients’ reactions to treatment, Oncohost Ltd.’s proteomics-based platform enables earlier prediction of paradoxical responses to immunotherapy that promote tumor growth in certain cancers. The artificial intelligence-powered host response profiling platform, called Prophet, could help identify the best combination of therapies and minimize adverse effects from treatments that are unlikely to be beneficial.

CLINICAL STUDY

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY